一个新的JAK2融合在T细胞前淋巴细胞白血病中
Ozgur Can Eren1, Robert Stuver2, Ting Zhou1
1Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Genes, chromosomes & cancer
|August 12, 2024
概括
T细胞前淋巴细胞白血病 (T-PLL) 是一种罕见的癌症. 研究人员在T-PLL患者中发现了一种新型基因融合,SMCHD1::JAK2,为这种侵袭性疾病提供了新的治疗点.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 遗传学是一种遗传学.
背景情况:
- T细胞前淋巴细胞白血病 (T-PLL) 是一种具有攻击性成熟的T细胞恶性瘤,预后不佳,没有标准治疗.
- 具有特征的遗传异常是inv(14),导致TCL1瘤基因激活.
- 之前的研究发现了JAK1/3和STAT5B突变,建议针对性治疗.
研究的目的:
- 确定导致T-PLL病变的新型遗传机制.
- 为了描述T-PLL患者新发现的基因融合.
- 报告该患者的临床过程和治疗反应.
主要方法:
- 使用了下一代测序技术.
- 基因分析发现了一种新型转位:t(9;18)(p24.1;p11.32).
- 对患者的临床数据和治疗反应进行了25个月的监测.
主要成果:
- 一个新的SMCHD1::JAK2基因融合被确定,由t(9;18) 产生的.
- 这次融合涉及SMCHD1异构45和JAK2异构14.
- 患者还拥有具有TCL1重新排列的特征inv.
- 用ruxolitinib和duvelisib治疗显示了25个月的疾病过程.
结论:
- SMCHD1::JAK2融合代表了T-PLL中以前未被描述的遗传事件.
- 这一发现扩大了对T-PLL遗传景观的理解.
- 针对JAK/STAT路径可能在T-PLL中有利于这种融合.
相关概念视频
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Lymphoid Cells and Tissues
1.1K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.1K
Tumor Immunotherapy
497
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
497
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K


